D-[1,2,3-13C3]glyceraldehyde (CAS 478529-54-3)

HLA-DO is a non-classical major histocompatibility complex (MHC) class II molecule that plays a specialized role in antigen presentation. It acts primarily as a modulator of HLA-DM function, another non-classical MHC class II molecule, to regulate the editing and stabilization of peptides within the MHC class II binding groove. Unlike most other MHC molecules, HLA-DO does not directly present antigens to T cells; rather, it influences the peptide repertoire presented by classical MHC class II molecules such as HLA-DR, HLA-DQ, and HLA-DP. HLA-DO typically operates within specialized intracellular compartments like endosomes and lysosomes, and its action is confined mainly to B cells and dendritic cells, which are specialized antigen-presenting cells. While HLA-DM generally enhances peptide loading onto MHC class II molecules, HLA-DO can inhibit this action, thereby providing a level of regulation and fine-tuning to the antigen presentation process. HLA-DO Inhibitors aim to modulate the activity of HLA-DO, either by reducing its expression, inhibiting its interaction with HLA-DM, or interfering with its intracellular trafficking. These inhibitors can range from small molecules to larger bioactive compounds. HLA-DO inhibitors would likely target the HLA-DO/HLA-DM interaction interface or act on upstream signaling pathways that regulate HLA-DO expression. Considering that HLA-DO functions intracellularly and its role is confined to specialized antigen-presenting cells, developing inhibitors with high specificity and bioavailability is a challenging task.